{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T05:54:25Z","timestamp":1772344465004,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,28]]},"DOI":"10.7759\/cureus.104462","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T04:58:27Z","timestamp":1772341107000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravenous Immunoglobulin for Refractory Streptococcal Toxic Shock Syndrome With Purpura Fulminans: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Rakshit","family":"Shetty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam Kiran","family":"Gandam Venkata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sruthi","family":"Bhuram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep Chakravarthy","family":"Bhuram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahi","family":"Chanpura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of Group A Streptococcus","volume":"27","author":"Walker MJ","year":"2014","unstructured":"Walker MJ, Barnett TC, McArthur JD, et al.. Disease manifestations and pathogenic mechanisms of Group A Streptococcus. Clin Microbiol Rev. 2014, 27:264-301. 10.1128\/CMR.00101-13","journal-title":"Clin Microbiol Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens DL","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al.. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014, 59:147-59. 10.1093\/cid\/ciu296","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/00365540310015944","article-title":"Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections","volume":"35","author":"Norrby-Teglund A","year":"2003","unstructured":"Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis. 2003, 35:683-9. 10.1080\/00365540310015944","journal-title":"Scand J Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00681.x","article-title":"The bacterial superantigen and superantigen-like proteins","volume":"225","author":"Fraser JD","year":"2008","unstructured":"Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol Rev. 2008, 225:226-43. 10.1111\/j.1600-065X.2008.00681.x","journal-title":"Immunol Rev"},{"key":"ref5","unstructured":"CDC. Streptococcal toxic shock syndrome (STSS) (Streptococcus pyogenes) 2010 case definition. (2021). Accessed: February 28, 2026: https:\/\/ndc.services.cdc.gov\/case-definitions\/streptococcal-toxic-shock-syndrome-2010\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis JR","year":"2005","unstructured":"Carapetis JR, Steer AC, Mulholland EK, et al.. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005, 5:685-94. 10.1016\/S1473-3099(05)70267-X","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(95)90647-9","article-title":"The pathogenesis of septic shock","volume":"30","author":"Sriskandan S","year":"1995","unstructured":"Sriskandan S, Cohen J. The pathogenesis of septic shock. J Infect. 1995, 30:201-6. 10.1016\/S0163-4453(95)90647-9","journal-title":"J Infect"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.1.23","article-title":"The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis","volume":"158","author":"Stevens DL","year":"1988","unstructured":"Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988, 158:23-8. 10.1093\/infdis\/158.1.23","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group","volume":"28","author":"Kaul R","year":"1999","unstructured":"Kaul R, McGeer A, Norrby-Teglund A, et al.. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999, 28:800-7. 10.1086\/515199","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30523-5","article-title":"Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study","volume":"21","author":"Babiker A","year":"2021","unstructured":"Babiker A, Li X, Lai YL, et al.. Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study. Lancet Infect Dis. 2021, 21:697-710. 10.1016\/S1473-3099(20)30523-5","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.12.5395-5398.1996","article-title":"Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G","volume":"64","author":"Norrby-Teglund A","year":"1996","unstructured":"Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U, Kotb M. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun. 1996, 64:5395-8. 10.1128\/iai.64.12.5395-5398.1996","journal-title":"Infect Immun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab I","year":"2013","unstructured":"Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat Rev Immunol. 2013, 13:176-89. 10.1038\/nri3401","journal-title":"Nat Rev Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1086\/376683","article-title":"Polyspecific intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Darenberg J","year":"2003","unstructured":"Darenberg J, Ihendyane N, Sj\u00f6lin J. Polyspecific intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003, 37:333-40. 10.1086\/376683","journal-title":"Clin Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu449","article-title":"Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study","volume":"59","author":"Linn\u00e9r A","year":"2014","unstructured":"Linn\u00e9r A, Darenberg J, Sj\u00f6lin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014, 59:851-7. 10.1093\/cid\/ciu449","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy401","article-title":"Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis","volume":"67","author":"Parks T","year":"2018","unstructured":"Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin Infect Dis. 2018, 67:1434-6. 10.1093\/cid\/ciy401","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05878-6","article-title":"Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children","volume":"46","author":"Weiss SL","year":"2020","unstructured":"Weiss SL, Peters MJ, Alhazzani W, et al.. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. 2020, 46:10-67. 10.1007\/s00134-019-05878-6","journal-title":"Intensive Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2220-9","article-title":"Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers","volume":"22","author":"Knaup H","year":"2018","unstructured":"Knaup H, Stahl K, Schmidt BM, et al.. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care. 2018, 22:285. 10.1186\/s13054-018-2220-9","journal-title":"Crit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455689-intravenous-immunoglobulin-for-refractory-streptococcal-toxic-shock-syndrome-with-purpura-fulminans-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T04:58:28Z","timestamp":1772341108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455689-intravenous-immunoglobulin-for-refractory-streptococcal-toxic-shock-syndrome-with-purpura-fulminans-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.104462","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}